特发性炎性肌病患者血清抗FHL1抗体的检测及临床意义  

Association of anti-FHL1 antibody and clinical manifestations in patients with inflammatory myopathy

作　　者：陈竹 刘柳 汪国生 李向培 厉小梅 CHEN Zhu;LIU Liu;WANG Guosheng;LI Xiangpei;LI Xiaomei(Department of Rheumatology and Immunology,Anhui Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,China)

机构地区：[1]安徽医科大学附属省立医院风湿免疫科,合肥230001

出　　处：《免疫学杂志》2021年第8期726-730,736,共6页Immunological Journal

摘　　要：目的探讨特发性炎性肌病(idiopathic inflammatory myopathy,IIM)患者血清中抗FHL1抗体的表达及其临床意义。方法收集2018年9月至2020年11月的IIM患者、其他自身免疫性疾病患者(类风湿关节炎、系统性红斑狼疮、干燥综合征、硬皮病)及健康人血清,采用酶联免疫吸附试验(ELISA)检测血清中抗FHL1抗体,结合临床资料进行统计分析。结果共纳入76名IIM患者,包括65名皮肌炎患者和11名多发性肌炎患者。ELISA检测发现IIM患者中抗FHL1抗体阳性者17名,阳性率22.4%。大多数其他自身免疫性疾病患者和健康人样本检测呈阴性。抗FHL1抗体阳性患者更易出现吞咽障碍(41.2%vs 10.2%,χ^(2)=6.895,P=0.009)。Log-Rank检验结果提示,抗FHL1抗体阳性患者比阴性患者生存时间更短(3.0月vs 21.0月,χ^(2)=2.605,P=0.107)。结论抗FHL1抗体与IIM特定的临床表现有关,有望成为新的IIM生物标志物,在协助临床诊断和判断预后上具有一定价值。This study was performed to assess anti-four and a half LIM domain 1(FHL1)antibody in serum of Chinese patients with idiopathic inflammatory myopathy(IIM)and explore the clinical significance of anti-FHL1.Serum samples were collected from IIM patients,patients with other autoimmune diseases(including rheumatoid arthritis,systemic lupus erythematosus,Sjogren′s syndrome,scleroderma)and healthy people from September 2018 to November 2020.Anti-FHL1 antibody in serum were detected by enzyme-linked immunosorbent assay(ELISA);association between antibody prevalence and clinical parameters were determined by statistical analyses.A total of 76 patients with IIM were enrolled,including 65 with dermatomyositis and 11 with polymyositis,in which 17 patients(22.4%)with IIM were found to be positive for anti-FHL1 antibody.Most samples from patients with other autoimmune diseases and healthy people were negative to anti-FHL1 antibody.Statistical analysis revealed that anti-FHL1-positive patients showed significantly higher prevalence of dysphagia(41.2%vs 10.2%,χ^(2)=6.895,P=0.009).Log-Rank test suggested that patients with positive anti-FHL1 antibody had shorter survival time(3.0 months vs 21.0 months,χ^(2)=2.605,P=0.107).Taken together,anti-FHL1 antibody is associated with specific clinical manifestation in IIM and serves as a promising biomarker in assisting clinical diagnosis and prognosis.

关 键 词：特发性炎性肌病 抗FHL1抗体 吞咽障碍 

分 类 号：R392.7[医药卫生—免疫学]